KR980700062A - 저 치밀성 리포솜 항균성 조성물(Low Rigidity Liposomal Antibacterial Composition) - Google Patents

저 치밀성 리포솜 항균성 조성물(Low Rigidity Liposomal Antibacterial Composition)

Info

Publication number
KR980700062A
KR980700062A KR1019970703952A KR19970703952A KR980700062A KR 980700062 A KR980700062 A KR 980700062A KR 1019970703952 A KR1019970703952 A KR 1019970703952A KR 19970703952 A KR19970703952 A KR 19970703952A KR 980700062 A KR980700062 A KR 980700062A
Authority
KR
South Korea
Prior art keywords
liposomal
therapeutic agent
bacteria
formulation
preparation
Prior art date
Application number
KR1019970703952A
Other languages
English (en)
Other versions
KR100438657B1 (ko
Inventor
쟈끌린 라가스
크리스띠앙 보락
세바스띠앙 끌레망-마죠르
Original Assignee
티모시 쟝 이몽
위니베흐시떼 드 몽트레알
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23430112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR980700062(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 티모시 쟝 이몽, 위니베흐시떼 드 몽트레알 filed Critical 티모시 쟝 이몽
Publication of KR980700062A publication Critical patent/KR980700062A/ko
Application granted granted Critical
Publication of KR100438657B1 publication Critical patent/KR100438657B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

본 발명은 항생제와 같은 적어도 하나의 치료제를 함유하는 리포솜 제제와, 이러한 제제의 투여를 통한 세균 감염의 치료방법에 관한 것이다. 콜레스테롤이 없으며, 중성 지질, 음이온성 지질 및 적어도 하나의 치료제를 함유하고, 리포솜 제제가 박테리아 세포 내부로의 치료제의 침투를 증진시키는 것을 특징으로 하는 저 치밀성 다층판성 리포솜 제제가 제공된다. 바람직한 지질의 조합은, 전체 지질 농도가 5 내지 85mM의 범위를 지니면서, 10:1 내지 15:1의 비율로 존재하는 디팔미토일포스파티딜콜린(dipalmitoylphosphatidylcholin) (DPPC) : 디미리프토일포스파티딜글리세롤(dimirystoylphosphatidylglycerol) (DMPG)이다.

Description

저 치밀성 리포솜 항균성 조성물(Low Rigidity Liposomal Antibacterial Composition)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 콜레스테롤이 없으며, 중성 지질, 음이온성 지질 및 적어도 하나의 치료제를 함유하고, 리포솜 제제가 박테리아 세포 내부로의 상기 치료제의 침투를 증진시키는 것을 특징으로 하는 저 치밀성 다층판성 리포솜 제제.
  2. 제 1 항에 있어서, 상기 중성 지질과 음이온성 지질은 약 5:1 내지 20:1의 비율로 존재하는 것을 특징으로 하는 리포솜 제제.
  3. 제 2 항에 있어서, 상기 중성 지질과 음이온성 지질은 약 7.5:1 내지 17.5:1의 비율로 존재하는 것을 특징으로 하는 리포솜 제제.
  4. 제 2 항에 있어서, 상기 중성 지질과 음이온성 지질은 약 10:1 내지 15:1의 비율로 존재하는 것을 특징으로 하는 리포솜 제제.
  5. 제 4 항에 있어서, 상기 중성 지질은 디팔미토일포스파티딜콜린(dipalmitoyl phosphatidylcholin) (DPPC)이고, 상기 음이온성 지질은 디미리프토일포스파티딜글리세롤(dimirystoylphosphatidylglycerol) (DMPG) 인 것을 특징으로 하는 리포솜 제제.
  6. 제 1 항에 있어서, 상기 치료제는 토브라마이신인 것을 특징으로 하는 리포솜 제제.
  7. 제 4 항에 있어서, 상기 치료제는 토브라마이신인 것을 특징으로 하는 리포솜 제제.
  8. 제 5 항에 있어서, 상기 치료제는 토브라마이신인 것을 특징으로 하는 리포솜 제제.
  9. 제 1 항에 있어서, 상기 제제는 적어도 하나의 박테리아 외부막과 외다당류 층을 통한 적어도 하나의 치료제의 통과를 증진시키는 것을 특징으로 하는 리포솜 제제.
  10. 약학적으로 또는 수의학적으로 적절한 투여량의 제 1항의 리포솜 제제의 투여를 포함하는, 동물에 있어서의 세균 감염의 치료 또는 예방방법.
  11. 적절하게 수용가능한 형태의 제 8항의 리포솜 제제의 투여를 포함하는, 동물에 있어서의 세균 감염의 뮤코이드 변종의 치료 또는 예방방법.
  12. 제 11 항에 있어서, 상기 박테리아는 녹농균(Pseudomonas aeruginosa)이고, 상기 동물은 낭종성 섬유증에 걸린 인간인 것을 특징으로 하는 치료 또는 예방방법.
  13. 제 10 항에 있어서, 상기 감염은 적어도 한가지 형태의 박테리아에 의해 일어나고, 상기 형태의 박테리아는 슈도모나스속(Pseudomonas), 부르크홀데리아속 (Burkholderia), 대장균속(Escherichia) 및 포도상구균속(Staphylococcus) 및 칸토모나스속(Xanthomonas)으로부터 선택된 것을 특징으로 하는 치료 또는 예방방법.
  14. 제 13 항에 있어서, 상기 감염은 적어도 한가지 형태의 박테리아에 의해 일어나고, 상기 형태의 박테리아는 녹농균(Pseudomonas aeruginoas), 부르크홀데리아세파시아 (Burkholderia capacia), 대장균(Escherichia coli), 황색 포도상구균(Staphylococcus aureus) 및 칸토모나스 말토필리아(Xanthomonas maltophilia)로부터 선택된 것을 특징으로 하는 치료 또는 예방방법.
  15. 약학적으로 또는 수의학적으로 적절한 형태의 제제를 투여하는 것을 포함하는, 동물에 있어서의 세균 감염의 치료, 예방 또는 진단용으로서의 제 1항의 리포솜 제제의 용도.
  16. 동물에 있어서의 세균 감염의 치료, 예방 또는 진단용 약제으로서의 제 1항의 리포솜 제제의 용도.
  17. 세균 감염의 치료 또는 예방을 위해 약학적으로 또는 수의학적으로 수용가능한 형태를 지닌 제 1항의 리포솜 제제를 함유한 항균성 제제.
  18. 제 15 항에 있어서, 상기 박테리아는 슈도모나스속(Pseudomonas), 부르크홀데리아속(Burkholderia), 대장균속(Escherichia), 포도상구균속(Staphylococcus) 및 칸토모나스속(Xanthomonas)으로 구성된 그룹으로 부터 선택된 것을 특징으로 하는 항균성 제제.
  19. 제 18 항에 있어서, 상기 박테리아는 녹농균(Pseudomonas aeruginosa), 부르크홀데리아 세파시아(Burkholderia capacia), 대장균(Escherichia coli), 황색 포도상구균(Staphylococcus aureus) 및 칸토모나스 말토필리아(Xanthomonas maltophi lia)로 구성된 그룹으로부터 선택된 것을 특징으로 하는 항균성 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970703952A 1994-12-23 1995-12-22 저치밀성리포솜항균조성물 KR100438657B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/363,416 US5662929A (en) 1994-12-23 1994-12-23 Therapeutic liposomal formulation
US08/363416 1994-12-23

Publications (2)

Publication Number Publication Date
KR980700062A true KR980700062A (ko) 1998-03-30
KR100438657B1 KR100438657B1 (ko) 2004-08-18

Family

ID=23430112

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703952A KR100438657B1 (ko) 1994-12-23 1995-12-22 저치밀성리포솜항균조성물

Country Status (14)

Country Link
US (1) US5662929A (ko)
EP (1) EP0806941B1 (ko)
JP (1) JP4523078B2 (ko)
KR (1) KR100438657B1 (ko)
AT (1) ATE235229T1 (ko)
AU (1) AU702463B2 (ko)
BR (2) BR9510423A (ko)
CA (1) CA2206296C (ko)
DE (1) DE69530124T2 (ko)
DK (1) DK0806941T3 (ko)
ES (1) ES2196092T3 (ko)
NZ (1) NZ297364A (ko)
PT (1) PT806941E (ko)
WO (1) WO1996019972A1 (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6365138B1 (en) * 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
WO2001097859A1 (en) * 2000-06-16 2001-12-27 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of chelated actinium-225 and uses thereof
CA2433280C (en) 2000-12-27 2010-09-21 Salus Pharma, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
JP2005525375A (ja) * 2002-03-05 2005-08-25 トランセイブ， インク． 生物活性物質をリポソーム又は脂質複合体内に封入する方法
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
ES2439727T3 (es) * 2002-10-29 2014-01-24 Insmed Incorporated Liberación sostenida de antiinfectantes
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
DE10255285A1 (de) * 2002-11-26 2004-06-03 Mcs Micro Carrier Systems Gmbh Selbst formende Phospholipid-Gele
ES2281021T3 (es) * 2003-10-15 2007-09-16 Pari Pharma Gmbh Formulacion liquida que contiene tobramicina.
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
CA2838111C (en) 2005-12-08 2016-01-19 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2013009761A1 (en) * 2011-07-13 2013-01-17 The Foundry, Llc Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
CN108743537B (zh) 2012-05-21 2021-06-11 英斯麦德公司 治疗肺部感染的系统
CN104884047A (zh) 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
MX2016014921A (es) 2014-05-15 2017-07-28 Insmed In Incorporated Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3177269A4 (en) 2014-08-04 2018-02-28 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
CA3075097A1 (en) * 2017-10-02 2019-04-11 Aridis Pharmaceuticals, Inc. Compositions and methods against p. aeruginosa infections
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN117017999A (zh) * 2023-09-20 2023-11-10 四川大学 一种夫西地酸磷脂复合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
PT100486B (pt) * 1992-05-14 1999-07-30 Ineti Inst Nac Engenh E Tecnol Aminoglucosidos lipossomais com altas eficacia de encapsulacao e actividade terapeutica, nomeadamente a netilmicina, e processo para a sua preparcao
AU3244393A (en) * 1992-12-02 1994-06-22 Vestar, Inc. Antibiotic formulation and process

Also Published As

Publication number Publication date
WO1996019972A1 (en) 1996-07-04
NZ297364A (en) 2000-01-28
ES2196092T3 (es) 2003-12-16
CA2206296A1 (en) 1996-07-04
BR9510423A (pt) 2003-01-07
ATE235229T1 (de) 2003-04-15
JP4523078B2 (ja) 2010-08-11
KR100438657B1 (ko) 2004-08-18
US5662929A (en) 1997-09-02
BRPI9510423B8 (pt) 2019-11-05
AU4251096A (en) 1996-07-19
EP0806941B1 (en) 2003-03-26
EP0806941A1 (en) 1997-11-19
AU702463B2 (en) 1999-02-25
DE69530124T2 (de) 2004-02-05
DK0806941T3 (da) 2003-07-21
MX9704679A (es) 1998-07-31
CA2206296C (en) 2007-05-22
PT806941E (pt) 2003-08-29
DE69530124D1 (de) 2003-04-30
JPH10511363A (ja) 1998-11-04

Similar Documents

Publication Publication Date Title
KR980700062A (ko) 저 치밀성 리포솜 항균성 조성물(Low Rigidity Liposomal Antibacterial Composition)
Beaulac et al. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria.
Ward et al. Topical agents in burn and wound care
Falagas et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections
EP1940437B1 (en) Compositions and methods for treating bacteria
Agger et al. Pseudomonas aeruginosa infections of intact skin
Gharib et al. Therapeutic efficacy of epigallocatechin gallate-loaded nanoliposomes against burn wound infection by methicillin-resistant Staphylococcus aureus
PT1581236E (pt) Libertação prolongada de anti-infecciosos
Dale et al. Therapeutic efficacy of “Nubiotics” against burn wound infection by Pseudomonas aeruginosa
US20080020025A1 (en) Composition for wound care and method of using same
Archer et al. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies
US7576054B2 (en) Compositions and methods for treating bacteria
Noronha et al. Local burn treatment-topical antimicrobial agents
Johnson et al. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis
FR2620620A1 (fr) Substance inhibitrice ou destructrice d'au moins un etre vivant unicellulaire renfermant du fluor f- et du lithium li+
Beaulac et al. In vitro bactericidal evaluation of a low phase transition temperature liposomal tobramycin formulation as a dry powder preparation against Gram negative and Gram positive bacteria
US20160331779A1 (en) Method of inactivating toxins using oxidative chlorine species
Selwyn The topical treatment of skin infection
Shetty et al. Highlights on role of antibiotics in periodontics
Cooper Medicines and other agents used in treatment, including emergency anesthesia kit and avian resuscitation protocol
HILL IMMUNOLOGY FOR THE PEDIATRICIAN
Kamel et al. The Role of Aztreonam in the Control of Gram-Negative Burn Wound Infection
Dale et al. Therapeutic Efficacy of''Nubiotics''against
RU2207131C1 (ru) Способ лечения хронической гонореи
Wertheim et al. Nasal carriage of Staphylococcus aureus: associated risks and preventive measures

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110621

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee